Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Xuan HuangDepartment of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmaceutical Sciences, Fudan University, Shanghai 201100, China.ORCID 0000-0002-5346-6029
Guangjun JingDepartment of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmaceutical Sciences, Fudan University, Shanghai 201100, China.
Kudelaidi KuerbanDepartment of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmaceutical Sciences, Fudan University, Shanghai 201100, China.
Jiajun FanDepartment of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmaceutical Sciences, Fudan University, Shanghai 201100, China.
Mei YuSchool of Pharmacy & Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau SAR, China.
Shanglin YangSchool of Pharmacy & Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau SAR, China.
Wei ChenSchool of Pharmacy & Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau SAR, China.
Litao HuangSchool of Pharmacy & Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau SAR, China.
Dianwen JuDepartment of Biological Medicines & Shanghai Engineering Research Center of Immunotherapeutics, School of Pharmaceutical Sciences, Fudan University, Shanghai 201100, China.
Yi Zhun ZhuSchool of Pharmacy & Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau SAR, China.ORCID 0000-0001-7700-8041
Li YeSchool of Pharmacy & Laboratory of Drug Discovery from Natural Resources and Industrialization, Macau University of Science and Technology, Macau SAR, China.ORCID 0000-0001-7048-6024
Funding
the Macau Science and Technology Development Fund 0019/2024/RIA1the Macau Science and Technology Development Fund FDCT 0148/2022/A3
6 · The paper itself
Abstract
Discoidin domain receptor 1 (DDR1), a collagen-binding receptor tyrosine kinase, plays a key role in extracellular matrix remodeling, tumor progression, and immune evasion. However, DDR1's comprehensive role across diverse cancers and its therapeutic potential in immune-resistant tumors remain poorly defined. We performed a pan-cancer analysis integrating bulk transcriptomic datasets, single-cell RNA sequencing, and pathway enrichment to evaluate
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
DDR1 Drives Collagen Remodeling and Immune Exclusion: Pan-Cancer Insights and Therapeutic Targeting in Pancreatic Ductal Adenocarcinoma. · full record | OpenQuestion